IONIQ Sciences recognized as “Most Innovative Non-Invasive Lung Cancer Testing Solution” and “Best Medical Technology Company 2021″
December 16, 2021
IONIQ Sciences, Inc. announced it has been awarded “Most Innovative Non-Invasive Lung Cancer Testing Solution” and “Best Medical Technology Company 2021” by Global 100. One of the critical innovations we believe that separates our IONIQ ProLung Test from other potential tests is in precisely what we are measuring. Using a novel application of bioimpedance technology, we believe we’re measuring the body’s systemic response to cancer. This enables earlier detection, and quite possibly detection of a wide array of cancers not tied to specific tumor types or sizes. Our ability to detect smaller 4-8mm pulmonary nodules in early cancer stages with greater accuracy than existing diagnostics is what earned us a ‘Breakthrough Device’ designation from the FDA.
Read the Original Announcement here »
For further information about IONIQ Sciences, Inc., please contact:
Andy Robertson | 1-801-736-0729 | acr@IONIQsciences.com
IONIQ Sciences, Vice President of Business Development
Recent News
- Nucleus Institute Convergence Point Groundbreaking
- EDWARDS LIFESCIENCES RECEIVES FDA APPROVAL FOR AUTUS VALVE
- Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4
- Owlet Announces Creation of Baby Safety Task Force to Educate, Innovate, and Advocate for Better Baby Safety Standards
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Freyya Closes Oversubscribed Pre-Seed Financing to Advance FDA Regulatory Milestones, Commercialization
